The cytokine TSLP has been shown to be a key factor in maintaining immune homeostasis
and regulating inflammatory responses at mucosal barriers. While the role of TSLP in type 2 …

Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with a bimodal distribution.
The progresses made in understanding its biology led to the development of targeted …

Novel biological subtypes and clinically important genetic aberrations (druggable lesions,
prognostic factors) have been described in B-other acute lymphoblastic leukemia (ALL) …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and accounts for
about a quarter of adult acute leukemias, and features different outcomes depending on the …

Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is associated with a high
frequency of copy number alterations (CNAs) in IKZF1, EBF1, PAX5, CDKN2A/B, RB1 …

Children with Down syndrome (DS) have a 20-fold increased risk of acute lymphoblastic
leukemia (ALL) and distinct somatic features, including CRLF2 rearrangement in∼ 50% of …

Deregulated expression of the type I cytokine receptor, CRLF2, is observed in 5–15% of
precursor B-cell acute lymphoblastic leukaemia (B-ALL). We have previously reported the …

Advances in our understanding of mechanisms of leukemogenesis and driver mutations in
acute lymphoblastic leukemia (ALL) lead to a more precise and informative sub …

Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a genetically
heterogeneous subtype of B-cell ALL characterized by chromosomal rearrangements and …

Recurrent clonal genetic alterations are the hallmark of Acute Lymphoblastic Leukemia
(ALL) and govern the risk stratification, response to treatment and clinical outcome. In this …